Trials / Conditions / Refractory Splenic Marginal Zone Lymphoma
Refractory Splenic Marginal Zone Lymphoma
4 registered clinical trials studyying Refractory Splenic Marginal Zone Lymphoma — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minoritie NCT06859008 | City of Hope Medical Center | Phase 1 |
| Withdrawn | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lym NCT04635683 | Yazeed Sawalha | Phase 1 |
| Withdrawn | Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma NCT04836832 | Narendranath Epperla | Phase 1 |
| Completed | Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic L NCT02332980 | Mayo Clinic | Phase 2 |